Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA)

Herz

Volumn 28, Issue 5, 2003, Pages 445-452

  Zahn, Ralf ^a   Haubelt, Hannelore ^b   Bechtloff, Sabine ^b   Schneider, Steffen ^a   Frilling, Birgit ^a   Rustige, Jörg ^c   Marsalek, Parvaneh ^c   Seidl, Karlheinz ^a   Senges, Jochen ^a   Hellstern, Peter ^b  

^a Heart Center Ludwigshafen   (Germany)

^b Inst of H/Transfus Med   (Germany)

^c LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Abciximab; Angioplasty; Hemorrhage; Heparin

Indexed keywords

ABCIXIMAB; HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MALE; PARTIAL THROMBOPLASTIN TIME; RELIABILITY; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BLOOD COAGULATION; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SENSITIVITY AND SPECIFICITY; TIME FACTORS; WHOLE BLOOD COAGULATION TIME;

EID: 10744225283     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-003-2349-3     Document Type: Article

References (22)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
2. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. Am J Cardiol 1997;79:286-91.
3. Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, Califf RM. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am J Cardiol 1998;81:36-40.
4. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
5. Olson JD, Arkin CF, Brandt JT, JA et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782-98.
6. Avendano A, Ferguson JJ. Comparison of Hemochron and Hemo-Tec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:907-10.
7. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984;63:394-8.
8. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75:559-62.
9. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614-7.
10. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82.
11. Ryan TJ, Bauman WB, Kennedy JW, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1993;88:2987-3007.
12. Bland JM, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995;346:1085-7.
13. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
14. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation 1995;91:2882-90.
15. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996;98:863-74.
16. Levy JH, Kelley A. In vitro effects of the platelet glycoprotein IIb/ IIIa receptor antagonists c7E3 Fab on the activated clotting time. Circulation 1997;96:3793-4.
17. Hardy JF, Belisle S, Robitaille D, Perrault J, Roy M, Gagnon L. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg 1996;112:154-61.
18. Hezard N, Metz D, Potron G, et al. Monitoring the effect of heparin bolus during percutaneous coronary angioplasty (PTCA): assessment of three bedside coagulation monitors. Thromb Haemost 1998;80:865-6.
19. Nuttall GA, Oliver WCJ, Beynen FM, Dull JJ, Murray MJ, Nichols WL. Intraoperative measurement of activated partial thromboplastin time a nd prothrombin time by a portable laser photometer in patients following cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993;7:402-9.
20. Reich DL, Yanakakis MJ, Vela-Cantos FP, DePerio M, Jacobs E. Comparison of bedside coagulation monitoring tests with standard laboratory tests in patients after cardiac surgery. Anesth Analg 1993;77:673-9.
21. Despotis GJ, Santoro SA, Spitznagel E, et al. On-site prothrombin time, activated partial thromboplastin time, and platelet count. A comparison between whole blood and laboratory assays with coagulation factor analysis in patients presenting for cardiac surgery. Anesthesiology 1994;80:338-51.
22. Bara L, Mardiguian J, Samama M. In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thromb Res 1990;57:585-92.